drugset / Trial / NCT01858948
SGA-induced Metabolic Syndrome in Bipolar Youth
Phase 3
Completed
19 enrolled
University of Cincinnati
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The investigators tested the hypothesis that long-chain omega-3 (LCn-3) fatty acid supplementation will attenuate the adverse cardiometabolic effects of second-generation antipsychotics exposure in first-episode adolescent manic patients.
Timeline
- Start
- 2013-07
- Primary completion
- 2018-04
- Completion
- 2018-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omega | Other / unclassified | 3 g | — |
| Subject | Quetiapine | Small molecule | 400 mg | — |
| Subject | Quetiapine | Small molecule | 600 mg | — |
Indications
No indication recorded.